Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotech in 2015 – the numbers

Last year witnessed the biotech sector's first retreat from a multi-year run of incredible performance on the public markets.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: NASDAQ biotech index over time.
Figure 2: Public biotech barometers.
Figure 3: Global biotech IPOs through the years.
Figure 4: Global biotech industry financing.

Author information

Authors and Affiliations

Authors

Supplementary information

Supplementary Information

Supplementary Table 1 (XLS 191 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C., Lähteenmäki, R. Public biotech in 2015 – the numbers. Nat Biotechnol 34, 709–715 (2016). https://doi.org/10.1038/nbt.3630

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3630

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research